Ülke: Malezya
Dil: İngilizce
Kaynak: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Pioglitazone Hydrochloride..
JETPHARMA SDN. BHD.
Pioglitazone Hydrochloride..
14 Tablets
INTAS PHARMACEUTICALS LIMITED
_CONSUMER MEDICATION INFORMATION LEAFLET_ PIOLET TABLETS PIOGLITAZONE (15MG, 30MG, 45MG) Page no. 1 WHAT IS IN THIS LEAFLET? 1. What Pioglitazone Tablets is used for? 2. How Pioglitazone Tablets works. 3. Before you use Pioglitazone Tablets. 4. H o w t o t a k e Pioglitazone Tablets. 5. W h i l e y o u a r e u sing Pioglitazone Tablets 6. Side effects. 7. After using Pioglitazone Tablets. WHAT PIOGLITAZONE TABLETS IS USED FOR? • P i o g l i t a z o n e i s in dicated in t he t reatment o f t ype 2 diabetes mellitus. • I t m a y b e u s e d o n t heir o w n o r i n c ombination with metformin and / or a s u l p h o n y l u r e a w hich are a l s o o r a l an ti-diabetic medicines. HOW P I O G L I T A Z O N E T ABLETS WORKS Pioglitazone belong the group of oral b l o o d g l u c o s e l o w e r i n g drugs. I t h e l p s c o n t r o l t h e l e v e l o f sugar in y our blood w hen you have t ype 2 d iabetes b y helping your body make better use of the insulin it produces. B E F O R E Y O U U S E PIOGLITAZONE TABLETS _WHEN YOU MUST NOT TAKE IT _ • Y o u ar e al l e r g i c t o pioglitazone or any o f t he o t h e r in g r e d i e n t s of pioglitazone tablets. • If you have heart failure • If you have liver disease _BEFORE YOU START TO TAKE IT _ • If you have a special type of diabetic eye d i s e a s e cal led macular oedema. • I f y o u a r e p l a n n i n g t o become pregnant. • If you are breast-feeding. • If you have polycystic ovary syndrome. There may be an increased possibility of your becoming p regnant because o f h o w y o u r medicine works. • If you have a problem with your liver or heart. • If you are under 18 years of a g e b e c a u s e u s e i n s uch p a t i e n t s is n ot recommended _TAKING OTHER MEDICINES _ • P l e a s e t e l l y o u r d o c t o r o r p h a r m a c i s t i f y o u ar e t a k i n g o r ha v e r ecently taken an y o ther medicines, i n c l u d i n g m edicines o b t a i n e d w i t h o u t a prescription. C H I L D R E N A N D A D O L E S C E N T S (BELO Belgenin tamamını okuyun
PIOLET (Pioglitazone Tablets 15, 30 & 45mg) COMPOSITION PIOLET 15 Each tablet contains: Pioglitazone Hydrochloride equivalent to Pioglitazone 15mg PIOLET 30 Each tablet contains: Pioglitazone Hydrochloride equivalent to Pioglitazone 30mg PIOLET 45 Each tablet contains: Pioglitazone Hydrochloride equivalent to Pioglitazone 45mg DOSAGE FORM Uncoated Tablet PRODUCT DESCRIPTION Piolet 15mg White to off white, round, biconvex, uncoated tablets debossed with 'P' on one side and '15' on other side. Piolet 30m g W hite t o of f w hite, f lat, round unc oated t ablets w ith be veled e dges de bossed w ith ‘PIO’ on one side and ‘30’ on the other side. Piolet 4 5mg W hite to o ff w hite, f lat, round unc oated t ablets w ith be veled e dges de bossed w ith ‘PIO’ on one side and ‘45’ on the other side. PHARMACODYNAMICS PROPERTIES Pharmacotherapeutic group: oral blood glucose lowering drugs; Thiazolidinediones; ATC code: A10BG03. Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pi oglitazone ha s be en s hown t o r educe h epatic g lucose out put a nd to i ncrease pe ripheral glucose disposal in the c ase of insulin resistance. Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. PHARMACOKINETIC PROPERTIES ABSORPTION: Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations o f u n c h a n g e d p i o g l i t a z o n e a r e u s u a l l y a c h i e v e d 2 hour s a f t e r a d m i n i s t r a t i o n . P r o p o r t i o n a l increases of t he pl asma c oncentration w ere obs erved f or dos es f rom 2 – 60 mg. Steady state is achieved after 4 –7 d Belgenin tamamını okuyun